Диссертация (1140642), страница 24
Текст из файла (страница 24)
Stepanenkov, V.T. Gorgol, A.V. Pavlyshin //Eur Acad Dermatol147Venerol. - 2003. - Vol. 15. - № 3. - P. 165.118. Lacey, N. Mite-related bacterial antigens stimulate inflammatory cells inrosacea / N. Lacey, S. Delaney, K. Kavanagh, F.C. Powell // Br J Dermatol. 2007. - Vol. 157. - P. 474-481.119. Marks, R.
Rosacea: hopeless hypothesis, marvelous myths and dermaldisorganization / R. Marks, G. Plewig // Ance and Related Disorders. – London:Martin Dunitz, 1989. – 293 p.120. Moore A., Kempers S., Murakawa G., Weiss J., Tauscher A., Swinyer L., et al.Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5%for the treatment of moderate to severe facial erythema of rosacea: results of a 1year open-label study. J. Drugs Dermatol. - 2014. Vol. 13. № 1. - P.
56-64.121. Nasir, A. A man with changes on nose / A. Nasir, A. Khachemoune // Journalof Americal Academy Dermatology (JAAD). - 2007. - Vol.57. - Issue 3. - P 551554.122. Orentreich, N. Dermabrasion / N. Orentreich, D.S. Orentreich // Dermatol.Clin. – 1995.
– Vol 13. - № 2. – P. 313-327.123. Parish, L.C. Acne rosacea and Helicobacter pylori betrothed /L.C. Parish, J.A.Witkowski // Int J Dermatol. - 1995. - Vol 34. - № 4. - P. 237-238.124. Pelle, M.T. Rosacea: II Therapy / M.T. Pelle, G.H. Crawford, V.D. James // JAm Acad. Dermatol. - 2004. - Vol.51 - № 4. - P. 499-512.125.
Phillips, T.J. An update on the safety and efficacy of topical retinoids / T.J.Phillips // Cutis. -2005.- Vol. 75. - № 2. – P. 14-22.126. Plewig, G. Akne und Rosazea / G. Plewig, A.M. Kligman // Berlin.:Heidelberg. Springer, 2000. - 725 p.127. Powel, F.C. Rosacea /F.C. Powel // N Engl J Med. - 2005. - Vol. 352. - P. 793803.128. Powell, F.C. Rosacea and the pilosebaceous follicle / F.C. Powell // Cutis. 2004. -Vol.
74. - № 3. - P. 32-34.129. Rebora, A. Helicobacter pylori in patient with rosacea /A.Rebora, F.Drago,A.Piccioto // Am J Gastroenterol. - 1994. - Vol. 89. - P. 1603-1604.130. Rebora, A. The red face: Rosacea / A.Rebora // Clin Dermatol. - 1993 - №11. 225-237.148131. Rorsman, H. Dermatology / H. Rorsman // Lund Univercity: Wolfe. - 1979.
P. 218-220.132. Schaefer, I. Prevalence of skin diseases in a cohort of 48, 655 employees inGermany / I.Schaefer, S.J. Rustenbach, L. Zimmer, M. Augustin // Dermatology. 2005. - Vol. 217. - № 2. - P. 169-172.133. Schmidt, J.B. Do sexual steroids contribute to the pathomechanism of rosacea?A study of estrogen and androgen receptors in acne rosacea / J.B. Schmidt, M.Raff, J. Spona // Acta Dermatol Venereol (Stockholm). - 1983. - Vol. 63. - P. 6466.134. Smith, J.R.
Expression of vascular endothelial growth factor and its receptorsin rosacea / J.R. Smith, V.B. Lanier, R.M. Braziel, K.M. Falkenhagen, C. White,J.T. Rosenbaum // Br. J Of Derm. - 2007. - Vol. 91. - № 2. - P. 226-229.135. Smith, M.F. Toll-like receptor (TLR)2 and TLR5, but not TLR4, are requiredfor Helicobacter pylori-inducted NF-kappa B activation and chemokine expressionby epithelial cells / M.F. Smith, A.
Michel, G. Li // J Biol Chem. - 2003. - Vol.278. - P. 32553-32560.136. Spoendlin, J. A study on the epidemiology of rosacea in the UK / J. Spoendlin,J. Voegel, S. Jick, C. Meier // Br J Dermatol. - 2012. - Vol. 167. - P. 598-605137. Stein Gold, L. Long-Term Safety of Ivermectin 1% Cream vs Azelaic Acid15% Gel in Treating Inflammatory Lesions of Rosacea: Results of Two 40-WeekControlled, Investigator-Blinded Trials / L. Stein Gold, L. Kircik, J.
Fowler, J.M.Jackson, J. Tan, Z. Draelos, A. Fleischer, M. Appell, M. Steinhoff, Ch. Lynde, J.Sugarman, H. Liu // Journal of Drug in Dermatology.-2014.- Volume 13. Issue11. - P.1380-1386.138. Stein, L. Efficacy and safety of ivermectin 1% cream in treatment ofpapulopustular rosacea: results of two randomized, double-blind, vehiclecontrolled pivotal studies / L. Stein, L. Kircik, J. Fowler, J.
Tan, Z. Draelos, A.Fleischer, M. Apell, M. Steinhoff, Ch. Lynde, J. Sugarman, H. Liu, J. Jacovella //Journal of Drugs Dermatology. - 2014. - Vol. 13. - Issue 3. P. 316-323.139. Stein, L. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel intreating inflammatory lesions of rosacea: results of two 40-week controlled,investigator-blinded trials / L. Stein, L. Kircik, J.
Fowler, J. Tan, Z. Draelos, A.149Fleischer, M. Apell, M. Steinhoff, Ch. Lynde, J. Sugarman, H. Liu, J. Jacovella //Journal of Drugs Dermatology. - 2014. - Vol. 13. - Issue 11. - P. 1380-1386.140. Taieb, A. Cost-effectiveness of ivermectin 1% cream in adult withpapulopustular rosacea in the United States / A. Taieb, L.
Stein Gold, S.R.Feldman, V. Dansk, E. Bertranou // Journal of managed care and specialtypharmacy. - 2016. - Vol. 22. - P. 654-666.141. Taieb, A. Superiority of ivermectin 1% cream over metronidazole 0,75%cream in treating inflammatory lesions of rosacea: a randomized, investigatorblinded trial / A. Taieb, J.P. Ortonne, T. Ruzicka, J.
Roszkiewicz, J. Bert-Jones,M.H. Peirone, J. Jacovella // British Journal of Dermatology. - 2015. - Vol. 172/ P. 1103-1110.142. Tan, J. Prevalence of rosacea in the general population of Germany and Russia- The RISE study /J. Tan, H. Schofer, E. Araviiskaia, F. Audibert, N. Kerrouche,M. Berg //JEADV - 2015. - Vol. 13556.
- P. 1-7.143. Tanghetti, E.A. Optimizing the use of topical brimonidine in rosaceamanagement: panel recommendations / E.A. Tanghetti, J.M. Jackson, K.T.Belasco, A. Frienrichs, F. Hougier, S. M. Johnson, F.A. Kerdel, D. Palceski,H.Ch. Hong, A. Hinek, M.J. Rueda Cadena // Journal of Drugs in Dermatology. Vol. 14. - Issue 1. - P.
1-13.144. Wilkin, J. Standard classification on rosacea. Report of the National RosaceaSociety Expert Committee on the Classification and Staging of Rosacea / J.Wilkin, M. Dahl, M. Detmar, L. Drake, A. Feinstein, R. Odom, F. Powell // J AmAcad Dermatol. - 2002/ - Vol. 46. - № 4. - P. 584-587.145. Wilkin, J.K. Rosacea. Pathophisiology and treatment /J.K.Wilkin //ArchDermatol. – 1994 - № 13. – P.
359-362.146. Xinxin, Ci. Avermectin exerts anti-inflammatory effect by downregulating thenuclear transcription factor kappa-B and mitogen-activated protein kinaseactivation pathway / Ci. Xinxin, L. Hongyu, Q.Yu, X. Zhang, L. Yu, N. Chen, Y.Song, X. Deng // Fundamental & Clinical Pharmacology. – 2009. – Vol. 23. – P.449-455.147.
Yamasaki, K. Increased serine protease activity and cathelicidin promotes skininflammation in rosacea / K. Yamasaki, A. Di Nardo, A. Bardan, M. Murakami, T.150Ohtake, A. Coda, R.A. Dorschner, C. Bonnart, P. Descargues, A. Hovnanian, V.B.Morhenn, R.L. Gallo // Nat.Med. - 2007. - Vol 13. - № 8. - P. 975-980.148. Yamasaki, K. Kallikrein-mediated proteolysis regulates the antimicrobialeffects of cathelicidins in skin / K. Yamasaki, J. Schauber, A. Coda, H.
Lin, R.A.Dorschner, N.M. Schechter, C. Bonnart, R.L., p. Descargues, A. Hovnanian, R.L.Gallo // FASEB J. - 2006 - Vol. 20. - № 12. - P. 2068-2080.149. Yamasaki, K. Kallikrein-mediated proteolysis regulates the antimicrobialeffects of cathelicidins in skin/ K. Yamasaki, A. Di Nardo, A. Bardan, M.Murakami, T. Ohtake, A.
Coda, R.A. Dorschner, C. Bonnart, P. Descargues, A.Hovnanian, V.B. Morhenn, R.L. Gallo // FASEB J. - 2006. - Vol.20. - № 12. - P.2068-2080.150. Yamasaki, K. Rosacea as a disease of cathelicidins and skin innate immunity /K. Yamasaki, R.L. Gallo //J. Investig. Dermatol. Symp. Proc. - 2011. - Vol 5. - №1. - P. 12-15.151. Yamasaki, K. The molecular pathology of rosacea / K. Yamasaki, L. Richard,R.L. Gallo // J Dermatol Sci.
- 2009. - Vol. 55. - P. 77-81.152. Yamasaki, K. The molecular pathology of rosacea / K. Yamasaki, R.L. Gallo//J Dermatol Sci - 2009. - Vol 55. - №2. - P. 77-81.153. Zhang, H. Risk factors for sebaceous gland diseases and their relationship togastrointestinal dysfunction in Han adolescents / H. Zhang, W. Liao, W. Chao, QChen, H. Zeng, C. Wu, S. Wu, H.L.
Hu // J. Dermatol. - 2008. - V.35. - № 9. - P.551-553..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
